Post
Three clinics, three break-evens
12 September 2026
Three clinics, three break-evens
Longevity is now the most crowded word in healthcare. Aesthetics clinics are adding a drip lounge and a biological age test. Primary care groups are renaming the executive check-up. Almost nobody has modelled what they are stepping into. An aesthetic clinic, a primary care clinic and a precision medicine clinic are not three versions of one business. They are three unrelated financial structures.
Aesthetics: moderate ticket, consumable-heavy, decided in a week, repeated every eight weeks, delivered by a therapist under supervision, rooms turning over in under an hour. Fastest to cash break-even, and the most commoditised.
Primary care: low ticket, high volume, insurance funded. Margin per encounter is set by the payer, not by you. Slower to break even, because you are building a population rather than running a campaign. What you buy for that patience is durability.
Precision medicine: highest ticket and by some distance the hardest. Heavy third-party cost of goods. Low throughput by design, because a comprehensive assessment consumes hours, not minutes. Long sales cycle, cash only, annual repeat frequency, highest capital per square metre. And the interpretation work that creates the actual value never appears as a billable line.
The failure is not scientific. It is a mental model failure. Operators bring aesthetic clinic instincts, fast payback and campaign-led acquisition, into a precision medicine cost structure. It does not show up in month one. It shows up in month nine, when the launch cohort has been assessed and the pipeline is empty.
Model it as its own business. Express break-even in contribution, then in room-hours and physician-hours, then test it against the schedule you actually have. If the capacity you need does not exist in the building, the plan is not ambitious. It is arithmetically impossible.
That is the work a clinic feasibility study should test before the doors open, and the work operational due diligence should test before an investor commits.
#Leadership #HealthcareLeadership #ExecutiveLeadership #OperationalExcellence #LeadershipDevelopment #AIandLeadership
